The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
The revenue growth comes amid increased demand for the company's molecular genetics products.
Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.
The kit detects the three most common aneuploidies associated with bladder cancer, as well as deletions of the 9p21.3 locus.
Sengenics is rebranding the technology Immunome and expects it to expand the company's footprint in the proteomics space.
The genomic products and services firm said that no assets or personnel will be transferred, but it will license its analysis software to Source BioScience.
The company plans to launch a suite of small cancer panels initially for research, but it could eventually seek regulatory approval for them as diagnostics.
The arrays feature the addition of newly identified genomic regions, as well as the removal of ones found to have no pathogenic significance.
While there are already many companies in the space, Agilent believes its relatively quick protocol and higher-throughput capacity will set it apart from competitors' products.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.